Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9099032 | 0.77 | GAA (0.50) | CASP7ALDH1A1L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL11619113 | 0.76 | SMN1; SMN2 (0.55) | ALDH1A1L3MBTL1KDM4EHSD17B10LMNA | |
| SCHEMBL11620517 | 0.74 | LMNA (0.47) | ALDH1A1KDM4EHSD17B10GAALMNA | |
| Hydrochloric Acid SCHEMBL9098740 | 0.73 | L3MBTL1 (0.47) | CASP7ALDH1A1L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL244336 | 0.71 | ALOX15 (0.58) | CASP7ALDH1A1L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL146852 | 0.71 | TSHR (0.55) | ALDH1A1KDM4EHSD17B10LMNATSHR | |
| SCHEMBL4255666 | 0.70 | RAB9A (0.54) | ALDH1A1KDM4EHSD17B10HPGDLMNA | |
| Hydrochloric Acid SCHEMBL244320 | 0.70 | ALOX15 (0.56) | CASP7ALDH1A1L3MBTL1KDM4EHSD17B10 | |
| SCHEMBL7702489 | 0.69 | MEN1 (0.47) | ALDH1A1L3MBTL1KDM4EHSD17B10HPGD | |
| SCHEMBL7699929 | 0.69 | TSHR (0.47) | ALDH1A1L3MBTL1KDM4EHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| CN-101772500-A | Imidazopyrazines as protein kinase inhibitors | SCHERING CORP | 2010-07-07 | — | — | CN | disclosed |
| EP-2182986-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2170892-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | CASP7 1171/4885CASP6 1433/4885ALDH1A1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.